In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer ( PFE -0.18%) was a hot stock during the pandemic, but it has been crashing in recent years. The company's COVID ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Parents won't be able to vaccinate healthy children 6 months to 5 years old if the FDA pulls Pfizer's COVID-19 vaccine authorization.

Pfizer › Pfizer (NYSE: PFE) has been a terrible investment over the past three years. Revenue and earnings have generally ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

Pfizer stock is incredibly cheap following management's raise of its 2025 adjusted earnings per share guidance. It's at just ...

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.